Neeraj Agarwal, Presidential Endowed Chair of Cancer Research at the Huntsman Cancer Institute (HCI), spotlights key bladder cancer updates from ESMO25.
“Kudos to Alexandra Drakaki at the ESMO25 outstanding talk despite the glitch with the slides.
Phase I study of LY3866288, a potent, highly isoform-selective FGFR3 inhibitor in FGFR3-altered advanced solid tumors (FORAGER-1) prelim efficacy and safety.”
“Another fantastic talk by Andrea Necchi at ESMO25.
At primary analysis, intravesical TAR-200 + cetrelimab showed high pCR, pOR and 1-y RFS in MIBC.
Clearance of urinary tumor DNA portends increase rPFS.”
“Wonderful and insightful discussion by the master Shilpa Gupta of the latest data in bladder cancer at ESMO25.
QOL data from Niagara trial, combination and next gen FGFR inhibitor.”
More posts featuring ESMO25.
